rs63749911 — PSEN1 F177L

PSEN1 F177L — A Rare Presenilin Variant That Raises the Alzheimer Amyloid Ratio

Presenilin-1¹¹ Presenilin-1
Encoded by the PSEN1 gene on chromosome 14; the catalytic aspartyl-protease subunit of the gamma-secretase complex is the primary molecular switch governing how the brain processes amyloid precursor protein (APP). When presenilin-1 works correctly, gamma-secretase trims APP into shorter, soluble peptides that are cleared without harm. When a PSEN1 mutation shifts that trimming process toward longer, aggregation-prone forms — particularly Aβ42 — the stage is set for the amyloid plaques that define Alzheimer's disease.

The F177L variant (c.529T>C, rs63749911) substitutes a leucine for the normal phenylalanine at position 177 of the presenilin-1 protein. It was identified in a large screening study of PSEN1 mutations in familial AD cases at referral centres and is listed as pathogenic by the AlzForum Mutations Database, which curates clinical and biochemical evidence for all known FAD mutations.

The Mechanism

Presenilin-1 forms the catalytic core of gamma-secretase, an intramembrane protease that makes sequential cuts in APP within the lipid bilayer. The position-177 phenylalanine sits in exon 6 of PSEN1²² exon 6 of PSEN1
Exon 6 encodes a portion of the protein spanning the transmembrane domain cluster near the N-terminal hydrophilic loop, a region critical for maintaining the precise geometry of the active-site aspartate residues. Computational structural analysis confirms that, unlike some silent polymorphisms at nearby positions, F177L alters the local structural properties of the transmembrane region.

Functionally, F177L has a relatively distinct biochemical fingerprint: it increases Aβ42 production and the Aβ42/Aβ40 ratio in transfected cells³³ increases Aβ42 production and the Aβ42/Aβ40 ratio in transfected cells
AlzForum biochemical data from heterologous expression systems; F177L biochemical data from Rogaeva et al. 2001 series while preserving most of the enzyme's total cleavage activity. This differentiates it from more disruptive mutations that broadly impair gamma-secretase function. The elevation of the Aβ42/Aβ40 ratio — the core biochemical lesion of familial AD — drives accelerated amyloid aggregation in the brain parenchyma and cerebral vasculature over decades.

The Evidence

Rogaeva et al. 2001⁴⁴ Rogaeva et al. 2001
Screening for PS1 mutations in a referral-based series of AD cases: 21 novel mutations. Neurology 57:621–625 identified F177L as one of 21 previously unreported PSEN1 mutations in a cohort of 414 consecutive patients referred for AD workup. Among 48 patients with PS1 mutations, 90% were symptomatic by age 60 — confirming the early-onset signature of PSEN1-related disease.

Zekanowski et al. 2006⁵⁵ Zekanowski et al. 2006
Exp Neurol 200:82–88 used F177L as a reference pathogenic variant in bioinformatic structural modeling, confirming it alters transmembrane region stability — a property shared with other bona fide pathogenic mutations but absent in neutral polymorphisms.

The DIAN study (McDade et al. 2018)⁶⁶ DIAN study (McDade et al. 2018)
Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91:e1295–e1306 established that in PSEN1 mutation carriers, CSF amyloid-beta and tau biomarkers become abnormal substantially before expected symptom onset — with the amyloid cascade beginning 15 or more years before clinical presentation. Structural MRI changes and cognitive decline follow, tracking toward the estimated age of onset inherited from family history.

Schultz et al. 2023⁷⁷ Schultz et al. 2023
Location of pathogenic variants in PSEN1 impacts progression. Aging Cell (DIAN data) showed that transmembrane-domain PSEN1 variants are associated with greater cognitive impairment and smaller hippocampal volumes than cytoplasmic variants — adding structural specificity to the expectation that F177L, located in the transmembrane cluster, may follow the more aggressive neurodegeneration trajectory seen in TM-domain mutations.

F177L is absent from gnomAD (0/22,800+ alleles tested), consistent with its status as a penetrant pathogenic allele — healthy people with this variant are rarely sequenced because they develop early-onset dementia before reaching old age.

Practical Actions

For heterozygous carriers — whether identified through diagnostic testing or cascade family screening — the evidence base for action is anchored to three priorities: presymptomatic biomarker monitoring, enrolment in prevention registries and trials, and specialist genetic counselling for the whole family.

CSF amyloid and tau, amyloid PET, and plasma phospho-tau 217 are now clinically validated tools for staging the presymptomatic AD cascade. Given the DIAN biomarker timeline, a carrier in their 30s may already have measurable amyloid accumulation 15–20 years before anticipated symptom onset. Baseline measurements and periodic follow-up — guided by a neurologist specialising in early-onset dementia — allow carriers to track their biological trajectory and inform decisions about clinical trial eligibility.

Enrolment in the DIAN⁸⁸ DIAN
Dominantly Inherited Alzheimer Network — an international observational registry and trial platform for autosomal dominant AD mutation carriers or comparable prevention studies (ADAD prevention trials) is a meaningful option for carriers of known pathogenic PSEN1 mutations.

Interactions

PSEN1 F177L acts via an autosomal dominant mechanism — one variant copy is sufficient for disease. It does not require a second hit. The primary interaction to consider is APOE ε4 (rs429358, rs7412), which influences the timing and severity of amyloid accumulation and is the strongest common genetic modifier of AD risk. In carriers of dominant PSEN1 mutations, APOE genotype may modulate the age at which symptoms become apparent, though PSEN1 mutations dominate the clinical trajectory. The amyloid-tau cascade in PSEN1 FAD also overlaps with tau pathology variants (MAPT haplotypes), but these interactions are not well-characterised for F177L specifically.